Download PDF
Semin Thromb Hemost 2019; 45(03): 297-301
DOI: 10.1055/s-0039-1683840
Review Article
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Flow Devices to Assess Platelet Function: Historical Evolution and Current Choices

Raisa Cintra Lomanto Santos Silva
1   Department of Pediatrics, Massachusetts General Hospital, Boston, Massachusetts
,
Eric Franklin Grabowski
2   Massachusetts General Hospital Comprehensive Hemophilia Treatment Center, Cardiovascular Thrombosis Laboratory, Pediatric Stroke Services, Massachusetts General Hospital, Boston, Massachusetts
› Author Affiliations
Further Information

Publication History

Publication Date:
25 March 2019 (online)

    Permissions and Reprints

Abstract

Platelet function testing, which began more than a hundred years ago, is a time-consuming and uncertain process. Simulating hemostasis and the blood vessel microenvironment in vitro is challenging, which poses a difficulty for diagnosing platelet dysfunction and mild von Willebrand disease (VWD). In an effort to simulate the rheological microenvironment within blood vessels, several blood flow devices have been introduced since the 1980s. These devices are capable of reproducing the shear rates found in arterioles and venules, and of incorporating endothelial cell monolayers and surfaces with adsorbed platelet-adhesive proteins. The authors will describe and review here the presently most well-known blood flow devices. The technologies inherent in these devices offer a combination of physiologic accuracy and small blood volume requirements in the evaluation of platelet disorders and mild VWD (or “symptomatic low von Willebrand factor”) in flowing whole blood, with the potential to individualize therapeutic options for and to achieve greater diagnostic accuracy in mild platelet disorders and VWD.

Keywords

microfluidics - platelet aggregation - platelet function testing - von Willebrand factor - von Willebrand disease
 

  • References

  • 1 Bizzozero J. On a new blood particle and its role in thrombosis and blood coagulation. Arquivos de Anatomia Patológica e Fisiologia de Medicina Clínica. Archiv für pathologische Anatomie und Physiologie und klinische Medizin 1982; 90: 261
    PubMedGoogle Scholar
  • 2 Grabowski EF, Curran MA, Van Cott EM. Assessment of a cohort of primarily pediatric patients with a presumptive diagnosis of type 1 von Willebrand disease with a novel high shear rate, non-citrated blood flow device. Thromb Res 2012; 129 (04) e18-e24
    CrossrefPubMedGoogle Scholar
  • 3 Choi J-L, Li S, Han J-Y. Platelet function tests: a review of progresses in clinical application. BioMed Res Int 2014; 2014: 456569
    PubMedGoogle Scholar
  • 4 Hellem AJ. The adhesiveness of human blood platelets in vitro. Scand J Clin Lab Invest 1960; 12 (Suppl): 1-117
    CrossrefPubMedGoogle Scholar
  • 5 Tsukada T, Ogawa T. On the mechanism of platelet retention by glass bead column. The platelet adhesiveness on glass head columns (Hellem II) [in Japanese]. Rinsho Ketsueki 1973; 14 (07) 777-784
    PubMedGoogle Scholar
  • 6 Hattori A, Ito S, Tsukada T, Koike K, Matsuoka M. Platelet adhesion and aggregation in the glass bead column method (Hellem-II): a scanning electron microscope study. Arch Histol Jpn 1974; 36 (04) 323-337
    PubMedGoogle Scholar
  • 7 Chandler AB. In vitro thrombotic coagulation of the blood; a method for producing a thrombus. Lab Invest 1958; 7 (02) 110-114
    PubMedGoogle Scholar
  • 8 Paul A, Avci-Adali M, Neumann B. , et al. Aptamers influence the hemostatic system by activating the intrinsic coagulation pathway in an in vitro Chandler-Loop model. Clin Appl Thromb Hemost 2010; 16 (02) 161-169
    CrossrefPubMedGoogle Scholar
  • 9 Slee JB, Alferiev IS, Levy RJ, Stachelek SJ. The use of the ex vivo Chandler Loop apparatus to assess the biocompatibility of modified polymeric blood conduits. J Vis Exp 2014; (90) 51871
    PubMedGoogle Scholar
  • 10 Born GVR. Aggregation of blood platelets by adenosine diphosphate and its reversal. Nature 1962; 194: 927-929
    PubMedGoogle Scholar
  • 11 O'Brien JM. Platelet aggregation: part II Some results from a new method of study. J Clin Pathol 1962; 15 (05) 452-455
    CrossrefPubMedGoogle Scholar
  • 12 Grabowski EF. Platelet aggregation in flowing blood in vitro. I. Production by controlled ADP convective diffusion and quantification by videodensitometry. Microvasc Res 1978; 16 (02) 159-182
    CrossrefPubMedGoogle Scholar
  • 13 Grabowski EF, Franta JT, Didisheim P. Platelet aggregation in flowing blood in vitro. II. Dependence of aggregate growth rate on ADP concentration and share rate. Microvasc Res 1978; 16 (02) 183-195
    CrossrefPubMedGoogle Scholar
  • 14 Chang Y-W, Liao C-H, Day Y-J. Platelet function analyzer (PFA-100) offers higher sensitivity and specificity than thromboelastography (TEG) in detection of platelet dysfunction. Acta Anaesthesiol Taiwan 2009; 47 (03) 110-117
    CrossrefPubMedGoogle Scholar
  • 15 Lehmann M, Ashworth K, Manco-Johnson M, Di Paola J, Neeves KB, Ng CJ. Evaluation of a microfluidic flow assay to screen for von Willebrand disease and low von Willebrand factor levels. J Thromb Haemost 2018; 16 (01) 104-115
    CrossrefPubMedGoogle Scholar
  • 16 Mammen EF, Alshameeri RS, Comp PC. Preliminary data from a field trial of the PFA-100 system. Semin Thromb Hemost 1995; 21 (Suppl. 02) 113-121
    Article in Thieme ConnectPubMedGoogle Scholar
  • 17 Kundu SK, Heilmann EJ, Sio R, Garcia C, Davidson RM, Ostgaard RA. Description of an in vitro platelet function analyzer--PFA-100. Semin Thromb Hemost 1995; 21 (Suppl. 02) 106-112
    Article in Thieme ConnectPubMedGoogle Scholar
  • 18 Favaloro EJ. Clinical utility of closure times using the platelet function analyzer-100/200. Am J Hematol 2017; 92 (04) 398-404
    CrossrefPubMedGoogle Scholar
  • 19 Michelson AD, Frelinger III AL, Furman MI. Current options in platelet function testing. Am J Cardiol 2006; 98 (10A): 4N-10N
    PubMedGoogle Scholar
  • 20 Harrison P. The role of PFA-100 testing in the investigation and management of haemostatic defects in children and adults. Br J Haematol 2005; 130 (01) 3-10
    CrossrefPubMedGoogle Scholar
  • 21 Hayward CP, Harrison P, Cattaneo M, Ortel TL, Rao AK. ; Platelet Physiology Subcommittee of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Platelet function analyzer (PFA)-100 closure time in the evaluation of platelet disorders and platelet function. J Thromb Haemost 2006; 4 (02) 312-319
    CrossrefPubMedGoogle Scholar
  • 22 Koscielny J, von Tempelhoff GF, Ziemer S. , et al. A practical concept for preoperative management of patients with impaired primary hemostasis. Clin Appl Thromb Hemost 2004; 10 (02) 155-166
    CrossrefPubMedGoogle Scholar
  • 23 Rechner AR. Platelet function testing in clinical diagnostics. Hamostaseologie 2011; 31 (02) 79-87
    Article in Thieme ConnectPubMedGoogle Scholar
  • 24 Ardillon L, Ternisien C, Fouassier M. , et al. Platelet function analyser (PFA-100) results and von Willebrand factor deficiency: a 16-year ‘real-world’ experience. Haemophilia 2015; 21 (05) 646-652
    CrossrefPubMedGoogle Scholar
  • 25 Podda G, Femia EA, Pugliano M, Cattaneo M. Congenital defects of platelet function. Platelets 2012; 23 (07) 552-563
    CrossrefPubMedGoogle Scholar
  • 26 Harrison P, Mackie I, Mumford A. , et al; British Committee for Standards in Haematology. Guidelines for the laboratory investigation of heritable disorders of platelet function. Br J Haematol 2011; 155 (01) 30-44
    CrossrefPubMedGoogle Scholar
  • 27 Harrison P. Assessment of platelet function in the laboratory. Hamostaseologie 2009; 29 (01) 25-31
    Article in Thieme ConnectPubMedGoogle Scholar
  • 28 Kweon OJ, Lim YK, Kim B, Lee M-K, Kim HR. Effectiveness of platelet function analyzer-100 for laboratory detection of anti-platelet drug-induced platelet dysfunction. Ann Lab Med 2019; 39 (01) 23-30
    CrossrefPubMedGoogle Scholar
  • 29 Bartels A, Sarpong Y, Coberly J. , et al. Failure of the platelet function assay (PFA)-100 to detect antiplatelet agents. Surgery 2015; 158 (04) 1012-1018 , discussion 1018–1019
    CrossrefPubMedGoogle Scholar
  • 30 Varon D, Dardik R, Shenkman B. , et al. A new method for quantitative analysis of whole blood platelet interaction with extracellular matrix under flow conditions. Thromb Res 1997; 85 (04) 283-294
    CrossrefPubMedGoogle Scholar
  • 31 Paniccia R, Priora R, Liotta AA, Abbate R. Platelet function tests: a comparative review. Vasc Health Risk Manag 2015; 11: 133-148
    CrossrefPubMedGoogle Scholar
  • 32 Anand SX, Kim MC, Kamran M. , et al. Comparison of platelet function and morphology in patients undergoing percutaneous coronary intervention receiving bivalirudin versus unfractionated heparin versus clopidogrel pretreatment and bivalirudin. Am J Cardiol 2007; 100 (03) 417-424
    CrossrefPubMedGoogle Scholar
  • 33 Shenkman B, Matetzky S, Fefer P. , et al. Variable responsiveness to clopidogrel and aspirin among patients with acute coronary syndrome as assessed by platelet function tests. Thromb Res 2008; 122 (03) 336-345
    CrossrefPubMedGoogle Scholar
  • 34 Neeves KB, Onasoga AA, Hansen RR. , et al. Sources of variability in platelet accumulation on type 1 fibrillar collagen in microfluidic flow assays. PLoS One 2013; 8 (01) e54680
    CrossrefPubMedGoogle Scholar
  • 35 Neeves KB, Maloney SF, Fong KP. , et al. Microfluidic focal thrombosis model for measuring murine platelet deposition and stability: PAR4 signaling enhances shear-resistance of platelet aggregates. J Thromb Haemost 2008; 6 (12) 2193-2201
    CrossrefPubMedGoogle Scholar
  • 36 Colace TV, Jobson J, Diamond SL. Relipidated tissue factor linked to collagen surfaces potentiates platelet adhesion and fibrin formation in a microfluidic model of vessel injury. Bioconjug Chem 2011; 22 (10) 2104-2109
    CrossrefPubMedGoogle Scholar
  • 37 Maloney SF, Brass LF, Diamond SL. P2Y12 or P2Y1 inhibitors reduce platelet deposition in a microfluidic model of thrombosis while apyrase lacks efficacy under flow conditions. Integr Biol 2010; 2 (04) 183-192
    CrossrefPubMedGoogle Scholar
  • 38 Colace TV, Muthard RW, Diamond SL. Thrombus growth and embolism on tissue factor-bearing collagen surfaces under flow: role of thrombin with and without fibrin. Arterioscler Thromb Vasc Biol 2012; 32 (06) 1466-1476
    CrossrefPubMedGoogle Scholar
  • 39 Grabowski EF. Platelet aggregation in flowing blood at a site of injury to an endothelial cell monolayer: quantitation and real-time imaging with the TAB monoclonal antibody. Blood 1990; 75 (02) 390-398
    CrossrefPubMedGoogle Scholar
  • 40 Grabowski EF, Van Cott EM, Bornikova L, Boyle DC. Differentiation of Patients with Type I von Willebrand Disease (vWD) and with Symptomatic Low Normal von Willebrand Factor (vWF) from those with Asymptomatic Low vWF, Using a Very High Shear Rate, High Image Resolution Blood Flow Chamber. Submitted for publication, September 2018, and presented at the 2017 Annual Meeting of the American Society of Hematology, Atlanta, GA, December 10, and published as an abstract in Blood 2017 ;130:2338
    PubMedGoogle Scholar
  • 41 Roest M, Reininger A, Zwaginga JJ, King MR, Heemskerk JW. ; Biorheology Subcommittee of the SSC of the ISTH. Flow chamber-based assays to measure thrombus formation in vitro: requirements for standardization. J Thromb Haemost 2011; 9 (11) 2322-2324
    CrossrefPubMedGoogle Scholar